A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01287338
Recruitment Status :
(Lack of definitive clinical results.)
A Randomized, Double-Masked, Placebo-Controlled, Proof of Concept Study to Evaluate the Short-term Safety and Efficacy of the QLT Proprietary Olopatadine Punctal Plug Delivery System in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.
Study Start Date :
Actual Primary Completion Date :
Actual Study Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
History of allergic conjunctivitis to ragweed for at least one year
Positive skin prick test to ragweed pollen within 12 months prior to visit 1
BCVA of at leat 20/400
Structural lid abnormalities (ectropion, entropion)
Active lid disease ( ie moderate or severe blepharitis, meibomianitis) that requires medical treatment
Presence of follicular conjunctivitis, anterior uveitis or preauricular lymphadenopathy
History of ophthalmic abnormality, including a history of dry eye
Perennial allergic rhinoconjunctivitis having significant allergy to animal dander that cannot be avoided during the study period
History of chronic bacterial or viral ocular infection, such as herpes keratitis, and/or presence of active bacterial or viral ocular infection
presence of mucous discharge, excess lacrimation or burning as a symptoms of ocular disease
Currently on any chronic ocular topical medications
Use of topical or systemic ocular medications during the study period
History of complications, adverse events, trauma or disease in the nasolacrimal area